AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • New Jersey
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated May 16, 2013 and effective on the date of consummation of the initial public offering of the Company’s common stock (the “Effective Date”), is by and between REGADO BIOSCIENCES, INC., a Delaware corporation (the “Company”) and ELLEN MCDONALD (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • New Jersey
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated May 16, 2013 and effective on the date of consummation of the initial public offering of the Company’s common stock (the “Effective Date”), is by and between REGADO BIOSCIENCES, INC., a Delaware corporation (the “Company”) and ALEXANDER R. GIAQUINTO, Ph.D. (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTAmended And • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • New Jersey
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated May 16, 2013 and effective on the date of consummation of the initial public offering of the Company’s common stock (the “Effective Date”), is by and between REGADO BIOSCIENCES, INC., a Delaware corporation (the “Company”) and STEVEN L. ZELENKOFSKE, D.O. (the “Executive”).
OFFICE LEASE AGREEMENT BY AND BETWEEN KEYSTONE 430 TT LLC (AS LANDLORD) AND REGADO BIOSCIENCES, INC. (AS TENANT) 430 Davis Drive Durham, North CarolinaLease Agreement • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • North Carolina
THIS LEASE AGREEMENT (the “Lease”) made and entered into as of the 1st day of May, 2013 (the “Effective Date”), by and between KEYSTONE 430 TT LLC, a Delaware limited liability company (“Landlord”), and REGADO BIOSCIENCES, INC., a Delaware corporation (“Tenant”):
CLINICAL DEVELOPMENT AND COLLOBORATION AGREEMENTConfidential Treatment • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • New York
THIS CLINICAL DEVELOPMENT AND COLLABORATION AGREEMENT (the “Agreement”) is made effective as of the 14th day of May, 2013 (the “Effective Date”), by and between NovaMedica, LLC (“NovaMedica”), a limited liability company organized under the laws of the Russian federation with an address of 10113 bldg 38, Sokolnichesky Val Street Moscow Russian Federation and Regado Biosciences, Inc. (“Regado” or “Company”), a corporation organized under the laws of the State of Delaware and having its place of business at 120 Mountain View Boulevard, Basking Ridge New Jersey 07920. For the purposes of this Agreement, “Party” means NovaMedica and Regado, individually, and “Parties” means NovaMedica and Regado, collectively.
ContractRegado Biosciences Inc • May 17th, 2013 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
REGADO BIOSCIENCES, INC. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations • California
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of May 10, 2013, by and between COMERICA BANK (“Bank”) and REGADO BIOSCIENCES, INC. (“Borrower”).
REGADO BIOSCIENCES, INC. TERMINATION AGREEMENTTermination Agreement • May 17th, 2013 • Regado Biosciences Inc • Pharmaceutical preparations
This TERMINATION AGREEMENT (the “Agreement”) is made as of the 16th day of May 2013, by and among Regado Biosciences, Inc., a Delaware corporation (the “Company”), the purchasers listed on Schedule A hereto (each an “Investor” and collectively the “Investors”).
